iRepertoire

Executive Summary

iRepertoire is a biotechnology company specializing in high-fidelity immune repertoire sequencing and analysis for TCR and BCR profiling. Founded in 2009 and headquartered in Huntsville, Alabama, the company offers proprietary dam-PCR and single-cell platforms that enable accurate, multi-chain immune receptor analysis. Its solutions support biomarker discovery and therapeutic development across immuno-oncology, infectious disease, autoimmunity, and cell therapy. As a pre-clinical stage company, iRepertoire has not yet disclosed funding rounds or valuation, but its technology addresses a critical need in immune profiling for research and drug development. The company's platforms are positioned to accelerate understanding of adaptive immune responses, potentially serving as key tools for biopharma partners and academic researchers. With the growing demand for precise immune monitoring in cell therapy and cancer immunotherapy, iRepertoire's offerings could gain significant traction. However, the company faces competition from established players in the space and must demonstrate commercial viability through partnerships or regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership or Licensing Deal with a Major Pharma40% success
• Q2 2026Launch of New Single-Cell Multi-Omics Platform60% success
• Q3 2026Series A Funding Announcement50% success